<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674399</url>
  </required_header>
  <id_info>
    <org_study_id>JS-OAP2-US01</org_study_id>
    <nct_id>NCT02674399</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Treatment of Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nature Cell Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRN Research, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nature Cell Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, randomized, controlled study with two arms to evaluate&#xD;
      JointStem as a treatment for subjects with osteoarthritis. Following a 2-week screening&#xD;
      period, approximately 30 subjects will be randomly assigned into one of the following two&#xD;
      arms in a 2:1 ratio (2 JointStem : 1 positive control). After each subject completes 6-month&#xD;
      visit (Visit 6) and the data management team confirms all data have no issue, the individual&#xD;
      database will be locked and the blinding will be open for the statistical analysis.Only&#xD;
      subjects who are assigned will be requested to visit the study center for 9-month and&#xD;
      12-month follow-up visits (Visits 7 and 8). To see long-term effects of JointStem, all&#xD;
      subjects who complete Visit 6 will be requested to visit the study center at 24-month after&#xD;
      the injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2016</start_date>
  <completion_date type="Actual">December 28, 2018</completion_date>
  <primary_completion_date type="Actual">March 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Comparing the baseline and 6-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline on Visual Analog Scale (VAS) in JointStem Group</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Comparing the baseline and 6-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI Improvement Evaluation in JointStem Group</measure>
    <time_frame>6 months</time_frame>
    <description>Comparing the baseline and 6-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on WOMAC Between JointStem and Positive Control Groups</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Comparing the changes of WOMAC scores between JointStem and positive control groups at 6 months Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on VAS Between JointStem and Positive Control Groups</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Comparing the changes of VAS scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Knee Injury &amp; Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Comparing the changes of KOOS values between JointStem and positive control groups at 6 months KOOS score = 100 - [{(average score of each item) * 100} / 4 ] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Comparing the changes of Lysholm Knee Scoring Scales between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Comparing the changes of IKDC scores between JointStem and positive control groups at 6 months IKDC score = {(sum of each item score) / 87} * 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Comparing the changes of RAND-36 scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on WOMAC in JointStem Group</measure>
    <time_frame>Baseline, 9 months and 12 months</time_frame>
    <description>Comparing the baseline and 9-month/12-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on VAS in JointStem Group</measure>
    <time_frame>Baseline, 9 months and 12 months</time_frame>
    <description>Comparing the baseline and 9-month/12-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of MRI Improvement Evaluation in JointStem Group</measure>
    <time_frame>Baseline, 6 months and 12 months</time_frame>
    <description>Comparing the baseline and 9-month/12-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12</measure>
    <time_frame>Baseline, 6 months, 9 months and 12 months</time_frame>
    <description>Comparing the baseline and 6-month/9-month/12-month Lysholm Knee Scoring Scale in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group</measure>
    <time_frame>baseline, 6 month, 9 month, 12 month</time_frame>
    <description>Comparing the baseline and 6-month/9-month/12-month KOOS scores in JointStem group KOOS score = 100 - [{(average score of each item) * 100} / 4 ] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group</measure>
    <time_frame>baseline, 6 month, 9 month, 12 month</time_frame>
    <description>Comparing the baseline and 6-month/9-month/12-month IKDC scores in JointStem group IKDC score = {(sum of each item score) / 87} * 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group</measure>
    <time_frame>baseline, 6 month, 9 month, 12 month</time_frame>
    <description>Comparing the baseline and 6-month/9-month/12-month RAND-36 scores in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>JointStem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synvisc-One</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyaluronic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JointStem</intervention_name>
    <arm_group_label>JointStem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synvisc-One</intervention_name>
    <arm_group_label>Synvisc-One</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject who can give written informed consent&#xD;
&#xD;
          -  Male or female of any race, aged 22-60&#xD;
&#xD;
          -  Subject who had osteoarthritis of knee diagnosed at least six months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Subject who has joint pain ≥ 40mm on VAS (Visual Analog Scale) at Screening&#xD;
&#xD;
          -  Subject who has swelling, tenderness and active range of motion ≥ Grade I at Screening&#xD;
&#xD;
          -  Subject who seeks invasive interventions of intra-articular injections&#xD;
&#xD;
          -  Subject who is willing to discontinue all pain medications for osteoarthritis except&#xD;
             rescue medication (&lt; acetaminophen 3.25 g per day) at least 72 hours prior to&#xD;
             screening and throughout the duration of study&#xD;
&#xD;
          -  Subject who has radiographic evidence of grade 3 to 4 osteoarthritis based on the&#xD;
             Kellgren and Lawrence radiographic criteria.&#xD;
&#xD;
          -  Female subject who is neither pregnant nor lactating&#xD;
&#xD;
          -  Subject who is able to comply with lifestyle guidelines, scheduled visits, treatment&#xD;
             plan, laboratory tests, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who has Body Mass Index (BMI) &gt; 35 kg/m2&#xD;
&#xD;
          -  Subject who has unstable knees&#xD;
&#xD;
          -  Subject who took any NSAID within two weeks from Screening&#xD;
&#xD;
          -  Subject who had any intra-articular injection therapy in any joint within 2 months&#xD;
             from Screening&#xD;
&#xD;
          -  Subject who has any clinically significant disease, which is judged by the&#xD;
             investigator to affect this clinical trial&#xD;
&#xD;
          -  Subject who has inflammatory arthropathy (rheumatoid, psoriatic, or avascular&#xD;
             necrosis), and post traumatic or septic arthritis&#xD;
&#xD;
          -  Subject who has chondrocalcinosis, Paget's disease, Villonodular synovitis, and other&#xD;
             non-OA joint diseases&#xD;
&#xD;
          -  Subject who has HIV/viral hepatitis&#xD;
&#xD;
          -  Subject who had knee surgery or radiation therapy in the affected joint within 6&#xD;
             months from Screening&#xD;
&#xD;
          -  Subject who had CVA attack within 6 months from Screening&#xD;
&#xD;
          -  Subject for whom the investigator judges the liposuction can cause any problem&#xD;
&#xD;
          -  Subject who has significant lab abnormalities&#xD;
&#xD;
          -  Subject who has history of local anesthetic allergy&#xD;
&#xD;
          -  Subject who took immunosuppressants such as Cyclosporin A or azathioprine within 6&#xD;
             weeks from Screening&#xD;
&#xD;
          -  (If a subject uses aspirin or plavix) Subject for whom it is determined that it would&#xD;
             not be safe to stop the aspirin/plavix therapy for 2 weeks prior to Visit 2&#xD;
&#xD;
          -  Subject who uses anticoagulants which cannot be stopped or corrected&#xD;
&#xD;
          -  Subject who had oral or intra-muscular corticosteroids within 30 days from Visit 2&#xD;
&#xD;
          -  Subject who had intra-articular corticosteroid injection in any joint within 30 days&#xD;
             from Visit 2&#xD;
&#xD;
          -  Subject who had intra-articular hyaluronic acid injection within 30 days from Visit 2&#xD;
&#xD;
          -  Subject who has known hypersensitivity (allergy) to hyaluronan (sodium hyaluronate)&#xD;
             preparations or gram positive proteins&#xD;
&#xD;
          -  Subject who has knee joint infections or skin diseases or infections in the area of&#xD;
             the injection site&#xD;
&#xD;
          -  Subject who has known systemic bleeding disorders&#xD;
&#xD;
          -  Subject who is an active drug/EtOH abuser&#xD;
&#xD;
          -  Subject who was enrolled in any other clinical trials within 2 months from Screening&#xD;
&#xD;
          -  Subject who the principal investigator considers inappropriate for the study due to&#xD;
             any other reasons than those listed above&#xD;
&#xD;
          -  Subject whose MRI scan results at screening do not demonstrate any sign of cartilage&#xD;
             damage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orthopedic Pain Specialists</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>June 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>JointStem</title>
          <description>JointStem : autologous adipose tissue derived mesenchymal stem cells (AdMSC) 1x10e8 cells At Visit 3 (Week 0, baseline), the randomized subject received a single intra-articular injection.</description>
        </group>
        <group group_id="P2">
          <title>Synvisc-One</title>
          <description>hyaluronic acid At Visit 3 (Week 0, baseline), the randomized subject received a single intra-articular injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>JointStem</title>
          <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
        </group>
        <group group_id="B2">
          <title>Synvisc-One</title>
          <description>hyaluronic acid&#xD;
Synvisc-One</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="6.98"/>
                    <measurement group_id="B2" value="52.1" spread="9.56"/>
                    <measurement group_id="B3" value="52.3" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.66" spread="9.222"/>
                    <measurement group_id="B2" value="169.46" spread="10.073"/>
                    <measurement group_id="B3" value="172.31" spread="9.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.31" spread="14.642"/>
                    <measurement group_id="B2" value="71.66" spread="20.569"/>
                    <measurement group_id="B3" value="78.2" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.903" spread="4.1938"/>
                    <measurement group_id="B2" value="24.572" spread="4.6408"/>
                    <measurement group_id="B3" value="26.154" spread="4.3971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group</title>
        <description>Comparing the baseline and 6-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>The primary endpoints were evaluated only in the JointsStem group.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group</title>
          <description>Comparing the baseline and 6-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
          <population>The primary endpoints were evaluated only in the JointsStem group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.121" spread="21.0415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline on Visual Analog Scale (VAS) in JointStem Group</title>
        <description>Comparing the baseline and 6-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>The primary endpoints were evaluated only in the JointsStem group.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Visual Analog Scale (VAS) in JointStem Group</title>
          <description>Comparing the baseline and 6-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
          <population>The primary endpoints were evaluated only in the JointsStem group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.5" spread="23.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MRI Improvement Evaluation in JointStem Group</title>
        <description>Comparing the baseline and 6-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.</description>
        <time_frame>6 months</time_frame>
        <population>The primary endpoints were evaluated only in the JointsStem group. And one patient was excluded from the table due to absence of MRI values.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Improvement Evaluation in JointStem Group</title>
          <description>Comparing the baseline and 6-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.</description>
          <population>The primary endpoints were evaluated only in the JointsStem group. And one patient was excluded from the table due to absence of MRI values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progress</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on WOMAC Between JointStem and Positive Control Groups</title>
        <description>Comparing the changes of WOMAC scores between JointStem and positive control groups at 6 months Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on WOMAC Between JointStem and Positive Control Groups</title>
          <description>Comparing the changes of WOMAC scores between JointStem and positive control groups at 6 months Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.505" spread="3.665"/>
                    <measurement group_id="O2" value="-17.129" spread="5.3281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on VAS Between JointStem and Positive Control Groups</title>
        <description>Comparing the changes of VAS scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on VAS Between JointStem and Positive Control Groups</title>
          <description>Comparing the changes of VAS scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.9" spread="4.90"/>
                    <measurement group_id="O2" value="-30.6" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Knee Injury &amp; Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups</title>
        <description>Comparing the changes of KOOS values between JointStem and positive control groups at 6 months KOOS score = 100 - [{(average score of each item) * 100} / 4 ] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Knee Injury &amp; Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups</title>
          <description>Comparing the changes of KOOS values between JointStem and positive control groups at 6 months KOOS score = 100 - [{(average score of each item) * 100} / 4 ] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.70" spread="2.888"/>
                    <measurement group_id="O2" value="14.83" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.40" spread="3.975"/>
                    <measurement group_id="O2" value="19.04" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.53" spread="3.937"/>
                    <measurement group_id="O2" value="15.94" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sport/Rec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="5.123"/>
                    <measurement group_id="O2" value="26.68" spread="7.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.68" spread="5.383"/>
                    <measurement group_id="O2" value="11.15" spread="7.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups</title>
        <description>Comparing the changes of Lysholm Knee Scoring Scales between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups</title>
          <description>Comparing the changes of Lysholm Knee Scoring Scales between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="3.97"/>
                    <measurement group_id="O2" value="19.9" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups</title>
        <description>Comparing the changes of IKDC scores between JointStem and positive control groups at 6 months IKDC score = {(sum of each item score) / 87} * 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups</title>
          <description>Comparing the changes of IKDC scores between JointStem and positive control groups at 6 months IKDC score = {(sum of each item score) / 87} * 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.74" spread="2.223"/>
                    <measurement group_id="O2" value="54.24" spread="3.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups</title>
        <description>Comparing the changes of RAND-36 scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups</title>
          <description>Comparing the changes of RAND-36 scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="3.80"/>
                    <measurement group_id="O2" value="14.9" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation (Physical)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="8.04"/>
                    <measurement group_id="O2" value="17.4" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation (Emotional)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="6.615"/>
                    <measurement group_id="O2" value="-6.74" spread="9.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.91"/>
                    <measurement group_id="O2" value="4.5" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional well-being</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="2.31"/>
                    <measurement group_id="O2" value="0.5" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.71" spread="2.964"/>
                    <measurement group_id="O2" value="16.16" spread="4.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.59" spread="4.211"/>
                    <measurement group_id="O2" value="14.7" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="2.516"/>
                    <measurement group_id="O2" value="3.13" spread="3.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on WOMAC in JointStem Group</title>
        <description>Comparing the baseline and 9-month/12-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
        <time_frame>Baseline, 9 months and 12 months</time_frame>
        <population>This measure was evaluated only in the JointsStem group.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on WOMAC in JointStem Group</title>
          <description>Comparing the baseline and 9-month/12-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment</description>
          <population>This measure was evaluated only in the JointsStem group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.216" spread="20.9653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.711" spread="19.7521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on VAS in JointStem Group</title>
        <description>Comparing the baseline and 9-month/12-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
        <time_frame>Baseline, 9 months and 12 months</time_frame>
        <population>This measure was evaluated only in the JointsStem group.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on VAS in JointStem Group</title>
          <description>Comparing the baseline and 9-month/12-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.</description>
          <population>This measure was evaluated only in the JointsStem group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.5" spread="25.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35" spread="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of MRI Improvement Evaluation in JointStem Group</title>
        <description>Comparing the baseline and 9-month/12-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.</description>
        <time_frame>Baseline, 6 months and 12 months</time_frame>
        <population>This measure was evaluated only in the JointsStem group. And one patient was excluded from the table due to absence of MRI values.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of MRI Improvement Evaluation in JointStem Group</title>
          <description>Comparing the baseline and 9-month/12-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.</description>
          <population>This measure was evaluated only in the JointsStem group. And one patient was excluded from the table due to absence of MRI values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Month 6 Improved -&gt; Month 12 Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Month 6 Improved -&gt; Month 12 No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Month 6 Improved -&gt; Month 12 Progress</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Month 6 No Change -&gt; Month 12 Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Month 6 No Change -&gt; Month 12 No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Month 6 No Change -&gt; Month 12 Progress</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Month 6 Progress -&gt; Month 12 Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Month 6 Progress -&gt; Month 12 No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Month 6 Progress -&gt; Month 12 Progress</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12</title>
        <description>Comparing the baseline and 6-month/9-month/12-month Lysholm Knee Scoring Scale in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
        <time_frame>Baseline, 6 months, 9 months and 12 months</time_frame>
        <population>This measure was evaluated only in the JointsStem group.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12</title>
          <description>Comparing the baseline and 6-month/9-month/12-month Lysholm Knee Scoring Scale in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
          <population>This measure was evaluated only in the JointsStem group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="22.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="25.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="23.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group</title>
        <description>Comparing the baseline and 6-month/9-month/12-month KOOS scores in JointStem group KOOS score = 100 - [{(average score of each item) * 100} / 4 ] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
        <time_frame>baseline, 6 month, 9 month, 12 month</time_frame>
        <population>This measure was evaluated only in the JointsStem group.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group</title>
          <description>Comparing the baseline and 6-month/9-month/12-month KOOS scores in JointStem group KOOS score = 100 - [{(average score of each item) * 100} / 4 ] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
          <population>This measure was evaluated only in the JointsStem group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at Month 6 (Symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.02" spread="15.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.03" spread="13.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.41" spread="18.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (Pain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.65" spread="20.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Pain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.98" spread="23.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Pain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.31" spread="21.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (ADL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.66" spread="23.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (ADL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.42" spread="25.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (ADL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.90" spread="23.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (Sport/Rec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.53" spread="23.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Sport/Rec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.42" spread="25.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Sport/Rec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.68" spread="24.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (QOL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.36" spread="24.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (QOL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.95" spread="27.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (QOL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.96" spread="29.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group</title>
        <description>Comparing the baseline and 6-month/9-month/12-month IKDC scores in JointStem group IKDC score = {(sum of each item score) / 87} * 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
        <time_frame>baseline, 6 month, 9 month, 12 month</time_frame>
        <population>This measure was evaluated only in the JointsStem group.</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group</title>
          <description>Comparing the baseline and 6-month/9-month/12-month IKDC scores in JointStem group IKDC score = {(sum of each item score) / 87} * 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
          <population>This measure was evaluated only in the JointsStem group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.03" spread="11.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.95" spread="12.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.63" spread="10.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group</title>
        <description>Comparing the baseline and 6-month/9-month/12-month RAND-36 scores in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
        <time_frame>baseline, 6 month, 9 month, 12 month</time_frame>
        <population>This measure was evaluated only in the JointsStem group</population>
        <group_list>
          <group group_id="O1">
            <title>JointStem</title>
            <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)&#xD;
JointStem</description>
          </group>
          <group group_id="O2">
            <title>Synvisc-One</title>
            <description>hyaluronic acid&#xD;
Synvisc-One</description>
          </group>
        </group_list>
        <measure>
          <title>Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group</title>
          <description>Comparing the baseline and 6-month/9-month/12-month RAND-36 scores in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment</description>
          <population>This measure was evaluated only in the JointsStem group</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at Month 6 (Physical Functioning)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="22.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Physical Functioning)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="23.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Physical Functioning)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="28.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (Role Limitation_Physical)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="36.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Role Limitation_Physical)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="38.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Role Limitation_Physical)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="40.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (Role Limitation_Emotional)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" spread="33.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Role Limitation_Emotional)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" spread="30.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Role Limitation_Emotional)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" spread="33.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (Energy/Fatigue)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Energy/Fatigue)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="16.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Energy/Fatigue)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="18.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (Emotional well-being)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Emotional well-being)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="11.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Emotional well-being)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="14.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (Social Functioning)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.82" spread="23.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Social Functioning)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.47" spread="20.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Social Functioning)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="25.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (Pain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.16" spread="21.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (Pain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.95" spread="22.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (Pain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.34" spread="21.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6 (General Health)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="13.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 9 (General Health)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="10.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (General Health)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="18.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>JointStem</title>
          <description>autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
        </group>
        <group group_id="E2">
          <title>Synvisc-One</title>
          <description>hyaluronic acid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Stiff knees</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Manager</name_or_title>
      <organization>Nature Cell co., ltd</organization>
      <phone>02-545-4137</phone>
      <email>tin50@stemcellbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

